Cancer Currents An NCI Cancer Research Blog

 

The findings were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) on 2 June 2019.

Of the 92 patients who were randomly assigned to receive olaparib, only 18 (20%) had their tumors partially or completely shrunk. But when the reactions occurred, they were relatively long-lasting.

“In a fraction of these patients, we are changing the trajectory of the disease,” said Heidi Kindler, MDD, University of Chicago, who led the polo trial.

To date, however, no improvement has been seen in patients with overall survival who have received olaparib. At the time of the ASCO presentation, participants in both groups had lived for approximately the middle of 18 months from the time they entered the trial.

Polo researchers are still following trial participants. But, looking at the preliminary results, which were published concurrently in the New England Journal of Medicine, “it does not seem possible that [in the final analysis] … there will be an overall survival advantage,” from Wells Messersmith, MD, University Said the MD of Colorado, who talked about the polo results in a discussion after the presentation.

Without improving overall survival,

“this study will … take future studies, grassroots rather than the possibility of combination therapy, rather than olaparib as a standard treatment for patients with advanced pancreatic cancer in BRCA1 and BRCA2” Is a harmful mutation, ”said UD Rudoff, PhD, MD, of NCI’s Center for Cancer Research, who was not involved in the study.

Dr. Rudolph noted that even though 20% of patients receiving olaparib had a reaction during the trial, so did 10% of the patients in the placebo group. Pancreatic cancer does not recur spontaneously,” Dr. Rudolph explained. 

Trying to uncover a damaged DNA repair mechanism 

specific inherited (germline) mutations in the BRCA1 and BRCA2 genes increase the risk of several cancer types, including breast, ovarian, and pancreatic cancers. Targeted therapy called PARP inhibitors has been approved for the treatment of some women with breast and ovarian cancer who have BRCA mutations.

Cancer cells with BRCA, which, studies have shown, make them particularly sensitive to PARP inhibitors.

The Polo trial, which was funded by AstraZeneca, tested the PARP inhibitor olaparib as a maintenance therapy — that is, treatment that is given after initial therapy to help prevent cancer from progressing.

To join the trial, they must have received at least 16 weeks of platinum-based chemotherapy without progressing to their disease.

Participants continued to take medication or placebo until their cancer progressed. During the trial, severe side effects occurred in 24% of participants who received olaparib and 15% who received placebo. Side effects prevented treatment in 5% of people in the olaparib group and 2% in the placebo group. 

According to preliminary results from clinical trials, the drug leniglomide (Revlimid) may delay the development of multiple myeloma in individuals with myeloma.

Smelling myeloma is a retrospective condition that replaces certain proteins in the blood and / or increases plasma cells in the bone marrow, but does not cause symptoms of the disease. However, half of those diagnosed with the condition will develop multiple myeloma within 5 years.

But by the time many myeloma symptoms appear, the disease can cause painful and debilitating health problems, including bone fractures and kidney failure.

In an NCI-backed clinical trial, researchers found that lenaloidomide — which is already used to treat multiple myeloma — may delay or slow the progression of myeloma.

Individuals who received the drug had a lower risk of developing multiple myeloma within 3 years. This was compared to individuals who were seen for symptoms of cancer during the same period, according to Sagar Loneal, chief medical officer of Winship Cancer Institute at Emory University. , Who led the trial.

LEAVE A REPLY

Please enter your comment!
Please enter your name here